VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

LLM 2021 | Actionable pathways that could be targeted in myeloma

Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses interesting and promising actionable pathways that could be targeted in the treatment of multiple myeloma. The development of compounds targeting genes such as MMSET, associated with the translocation t(4; 14), is currently in its early stages. Agents targeting RAS mutations are also under development. Additionally, targeting the BRAF mutation may be of interest in myeloma as well. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter